Genes and Diseases (Mar 2024)
Bortezomib depended on PRDM1 and TP53 to exert therapeutic effect in activated B-cell-like diffuse large B-cell lymphoma
- Jing Tang,
- Yue Li,
- Jiazhu Wu,
- Haorui Shen,
- Hua Yin,
- Jinhua Liang,
- Li Wang,
- Jianyong Li,
- Yi Xia,
- Wei Xu
Affiliations
- Jing Tang
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China
- Yue Li
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China
- Jiazhu Wu
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China
- Haorui Shen
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China
- Hua Yin
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China
- Jinhua Liang
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China
- Li Wang
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China
- Jianyong Li
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China
- Yi Xia
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China; Corresponding author. Fax: +86 25 83781120.
- Wei Xu
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China; Corresponding author. Fax: +86 25 83781120.
- Journal volume & issue
-
Vol. 11,
no. 2
pp. 550 – 553
